secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001193125-21-317685
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q3 net loss $88.8M; mitapivat gets FDA Priority Review with PDUFA Feb 17, 2022
--------------------------------------------------------------------------------

- Net loss $88.8M vs $99.0M in Q3 2020; R&D $64.0M up from $51.9M on trial start-up costs.
- Cash $1.4B; expects to fund operations through cash-flow positivity without equity raise.
- FDA granted Priority Review for mitapivat in PK deficiency; PDUFA date Feb. 17, 2022.
- Initiated Phase 3 ENERGIZE and ENERGIZE-T for thalassemia; plan to start RISE UP sickle cell study by year-end.
- Repurchased 5.3M shares at $47.94 avg; $800M+ of $1.2B buyback completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312521317685/0001193125-21-317685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312521317685/d199842d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-317685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer